- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02709330
ALS Reversals - Lunasin Regimen
An Open-label, Single-center, 12-month Trial of a Lunasin Regimen for Patients With Amyotrophic Lateral Sclerosis (ALS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary hypothesis is that a supplement regimen containing Lunasin (referred to as the Lunasin regimen) can decrease the rate of ALSFRS-S progression by 50% relative to matched historic controls.
ALS is a devastating motor neuron disease that causes rapidly progressive muscle weakness, disability and premature death. In spite of a large number of attempted ALS trials, there are no significant disease-modifying therapies for this condition.
It was recently reported that a patient with a validated diagnosis of ALS, had experienced dramatic objective improvement in speech, swallowing and limb strength while taking a supplement regimen containing Lunasin. Several other patients with ALS have also reported improvement on this Lunasin regiment, though records were not obtainable to validate these.
The Lunasin regimen will consist of:
- LunaRich X Capsules
- Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants'
- Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids'
Dosages will be titrated up to target over the first 6 days. The subject will take the highest tolerated dosing for the remainder of the 12-month study.
There are 3 in-clinic visits which occur at screening/baseline, Month 1 and Month 12. For Months 2-11, participants will make "virtual visits" by measuring their own ALSFRS-R score and weight and will record it in the PatientsLikeMe website. They will also self-report any perceived efficacy, compliance, adverse events and changes in concomitant medications.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke Medicine / Neurology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, aged at least 18 years.
- Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.
- Patient is able to understand and express informed consent (in the opinion of the site investigator).
- Patient has access to the Internet on a desktop computer, laptop, or tablet and has a working email address.
- Patient or caregiver is willing and able to use a computer and enter data on a secure website.
- Patient is able to read and write English.
- Women must not be able to become pregnant (e.g., post-menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal contraception, for example patch or contraceptive ring), intrauterine device (IUD) in place for ≥ 3 months, barrier method in conjunction with spermicide, or another adequate method.
Exclusion Criteria:
- Patient is taking other experimental treatments for ALS.
- Prior side effects from Lunasin.
- Known soy allergy.
- Patient has a medical or psychiatric illness that could in the investigator's opinion interfere with the patient's ability to participate in this study.
- Pregnant women or women currently breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lunasin regimen
The Lunasin regimen consists of:
It will be suggested that patients open the LunaRich X capsules and mix the contents of these as well as the other 2 ingredients in water to make a shake. If patients do not tolerate advancing to the next dosage, they will be asked to drop back to the highest dosage they could tolerate. |
LunaRich X Capsules, Reliv Now, ProVantage
|
Active Comparator: Historical controls
For each enrolled participant, matched historical controls will be identified from the PatientsLikeMe database.
Participants will be matched according to their ALSFRS-R progression rate before they start on the Lunasin regimen (estimated by assuming their score was normal at 48 on the date of symptom onset).
|
Matched historical controls will be identified from the PatientsLikeMe database.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Revised ALS Functional Rating Scale (ALSFRS-R)
Time Frame: Screening/baseline - 12 months
|
ALSFRS-R is a quickly administered (five minute) ordinal rating scale used to determine patient's assessment of their capability and independence in 13 functional activities.
All 13 activities are relevant in ALS.
Each task is rated on a five-point scale from 0 = can't do, to 4 = normal ability, with a total score of 52 points.
Reported is the rate of change in total points per month.
|
Screening/baseline - 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in H3 Histone Acetylation
Time Frame: Screening/baseline, Month 1
|
Participants, ALS controls (not on Lunasin) and healthy controls (not on Lunasin) had blood drawn at baseline and 1 month time points.
Histones were extracted from blood cells.
Western blots were used to look at specific histone acetylation patterns that Lunasin had reportedly altered in cell cultures (H3K9K14ac2 and H4K5K8K12K16).
Integrated density values for AcH3 protein bands were normalized for total H3.
Percent H3 values for the 1 month time point were normalized to that of the baseline visit.
Results were analyzed by one-way ANOVA.
|
Screening/baseline, Month 1
|
Percent Agreement Between the Weights Obtained by Patients and Study Coordinator
Time Frame: Month 1, Month 12
|
To confirm that participants can accurately measure their own weight, even as they become more disabled by ALS, the investigators will compare the participant-generated weight with the weight obtained by the study coordinator at the Month 1 and Month 12 visits.
A simple description of the accuracy (percent agreement between the weights) will be used.
|
Month 1, Month 12
|
Enrollment Rate
Time Frame: Screening/baseline - Month 12
|
Rate of enrollment in reaching the 50 participants required to fill the trial.
|
Screening/baseline - Month 12
|
Retention Rate
Time Frame: Month 12
|
Percentage of surviving participants who completed the month 12 visit.
|
Month 12
|
Frequency of ALS Reversals
Time Frame: Screening/baseline - Month 12
|
The percentage of enrolled participants experiencing an ALSFRS-R improvement of at least 4 points lasting at least 12 months.
|
Screening/baseline - Month 12
|
ALSFRS-R Accuracy
Time Frame: Month 1
|
To confirm that participants can accurately measure their own ALS Functional Rating Scale (Revised, ALSFRS-R), the investigators will compare the ALSFRS-R obtained by the coordinator with that obtained by the participants themselves at the Month 1 Visit.
Correlational analysis between these 2 scores will be performed with Spearman's rho.
|
Month 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard Bedlack, M.D., Ph.D., Associate Professor of Neurology
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00063754
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ALS (Amyotrophic Lateral Sclerosis)
-
Northwestern UniversityCompletedAmyotrophic Lateral Sclerosis (ALS) | Lou Gehrig's Disease | Primary Lateral Sclerosis (PLS) | Familial Amyotrophic Lateral Sclerosis | ALS With Frontotemporal Dementia (ALS/FTD) | Motor Neuron Disease (MND) | Sporadic ALS (SALS)United States
-
Dallas VA Medical CenterRecruitingAmyotrophic Lateral Sclerosis (ALS)United States
-
St. Joseph's Hospital and Medical Center, PhoenixEmory University; Mitsubishi Tanabe Pharma America Inc.Active, not recruitingALS (Amyotrophic Lateral Sclerosis)United States
-
Taipei Veterans General Hospital, TaiwanUnknownDevelopment and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS.ALS (Amyotrophic Lateral Sclerosis)Taiwan
-
Brainstorm-Cell TherapeuticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Phoenix Neurological Associates, LTDInstitute for EthnomedicineUnknown
-
Skulpt, Inc.National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedAmyotrophic Lateral Sclerosis (ALS)United States
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
Clinical Trials on Lunasin Regimen
-
Medical University of South CarolinaTerminatedHematological MalignanciesUnited States
-
Pearl Therapeutics, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
GlaxoSmithKlineCompleted
-
University of BedfordshireUnknownCardiovascular Diseases | Diabetes | Sedentary Lifestyle | Type 2 Diabetes | Sedentary Behavior | Cardiovascular Risk FactorUnited Kingdom
-
Novartis PharmaceuticalsActive, not recruitingStudy of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis (ONWARDS)OsteoarthritisTaiwan, Spain, United Kingdom, United States, Argentina, Australia, Denmark, India, China, Czechia, Canada, Japan, Poland, Mexico, Estonia
-
Florida State UniversityAlliance for Potato Research and EducationCompletedOverweight and Obesity | Type2 Diabetes | Arterial Stiffness | Cardiometabolic SyndromeUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UnknownCritical Illness | Respiratory Insufficiency | Fluid Overload | Respiratory InfectionNetherlands
-
Masonic Cancer Center, University of MinnesotaNational Institutes of Health (NIH)Completed
-
Huashan HospitalNot yet recruitingMultidrug Resistant TuberculosisChina
-
Fudan UniversityNot yet recruitingColorectal Neoplasms | Intestinal NeoplasmsChina